Comparative Pharmacology
Head-to-head clinical analysis: GENTACIDIN versus KANAMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTACIDIN versus KANAMYCIN.
GENTACIDIN vs KANAMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis.
5-7 mg/kg IV every 24 hours.
15 mg/kg/day IM or IV in divided doses every 12 hours. Maximum daily dose: 1.5 g.
None Documented
None Documented
2-3 hours in adults with normal renal function; extended to 24-48 hours in anuria or severe renal impairment, requiring dose adjustment.
Clinical Note
moderateKanamycin + Digoxin
"The serum concentration of Digoxin can be decreased when it is combined with Kanamycin."
Clinical Note
moderateKanamycin + Digitoxin
"The serum concentration of Digitoxin can be decreased when it is combined with Kanamycin."
Clinical Note
moderateKanamycin + Deslanoside
"The serum concentration of Deslanoside can be decreased when it is combined with Kanamycin."
Clinical Note
moderateKanamycin + Acetyldigitoxin
Terminal elimination half-life is 2-4 hours in patients with normal renal function (creatinine clearance >80 mL/min). In anuria, half-life may extend to 50-100 hours, necessitating dose adjustment based on renal function.
Renal: 95-98% unchanged via glomerular filtration; biliary/fecal: <2%.
Primarily renal excretion via glomerular filtration; approximately 80-90% of administered dose is excreted unchanged in urine within 24 hours. Biliary/fecal excretion is minimal (<1%).
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic
"The serum concentration of Acetyldigitoxin can be decreased when it is combined with Kanamycin."